PEIJIA-B (09996) has released a statement indicating that the group expects revenue for the first half of 2026 to be approximately RMB 415 million to RMB 435 million, representing a year-on-year increase of about 17.4% to 23.1%.
The group's steady revenue growth is primarily attributed to two key areas: (i) continued expansion in the transcatheter valve therapy business, driven by the successful commercialization of new indication products and leveraging the group's established transcatheter aortic valve replacement (TAVR) commercialization capabilities to seize new market opportunities from the approved aortic regurgitation (AR) indication; and (ii) sustained growth in the neurointerventional business, fueled by the ongoing market penetration of its self-developed products and the expansion of its product portfolio through strategic collaborations.
In the transcatheter valve therapy segment, the group continues to solidify its leading position in China's transfemoral TAVR market. As of June 30, 2026, the group's TAVR product portfolio has expanded hospital coverage to over 850 hospitals in the Greater China region, an increase of approximately 70 hospitals compared to December 31, 2025.
During the reporting period, total TAVR implantations (including those for aortic stenosis (AS) and AR indication products) reached approximately 2,830 units, based on implantation volume, representing a significant increase of about 36.5% compared to the six months ended June 30, 2025.
The growth in the transcatheter valve therapy business has been particularly supported by the successful commercialization of the TaurusTrio® transcatheter aortic valve system, the group's dedicated TAVR system designed for treating AR. Leveraging the group's extensive experience and established commercial infrastructure from years of TAVR commercialization in the AS market, the TaurusTrio® has rapidly gained market adoption since its launch. As a novel solution addressing unmet clinical needs in AR treatment, the TaurusTrio® has accelerated clinical application and received widespread market recognition due to its product design advantages, safety performance, and standardized surgical procedures. During the reporting period, the TaurusTrio® completed over 660 implantations in mainland China, demonstrating strong clinical acceptance and commercialization potential.
Simultaneously, leveraging the differentiated performance of the group's 3D steerable TAVR system, the TaurusMax®, the group's AS indication product portfolio has maintained growth in an increasingly competitive market environment.
In the neurointerventional business, benefiting from a model combining independent innovation with strategic partnerships, the group continues to expand its product portfolio and enhance its market competitiveness. The group's proprietary products, including the Syphonet® thrombectomy stent, Fastunnel® delivery balloon dilation catheter, and DCwire® micro guidewire, have gained increasing market recognition due to their differentiated designs and superior performance, driving sustained market penetration and revenue growth. Additionally, through strategic collaborations, the group has further expanded its neurointerventional business and launched products co-developed with partners, including the YonFlow® flow diverter and the Qida® disposable neurovascular sheath, which have achieved expanded commercial scale during the reporting period and contributed to additional revenue growth.